https://ntp.niehs.nih.gov/go/28760

Transgenic model evaluation II (Glycidol): Target Organs and Levels of Evidence for GMM-13

Toxicology and Carcinogenesis Study of Glycidol (CASRN 556-52-5) in Genetically Modified Haploinsufficient p16Ink4a/p19Arf Mice (Gavage Study)

Chemical (Study Title)
CASRN 		Peer Review Date Route/Exposure Levels Study Laboratory
Transgenic model evaluation II (Glycidol)
556-52-5 		08/28/2006 Gavage
0, 25, 50, 100, or 200 mg/kg		 Battelle Columbus Laboratory

Levels of evidence information for Carcinogenesis and Genetic Toxicology Studies of Glycidol in Haploinsufficient p16Ink4a/p19Arf Mice
  Male Haploinsufficient p16Ink4a/p19Arf Mice Female Haploinsufficient p16Ink4a/p19Arf Mice
  40 Weeks 40 Weeks
Levels of Evidence Clear Evidence Some Evidence
May have been related None
  • Forestomach: squamous cell papilloma 0/15 0/15 0/15 1/15 3/15
Neoplastic Lesions
  • All organs: histiocytic sarcoma 2/15 6/15 9/15 5/15 11/15
  • Lung: alveolar/bronchiolar adenoma 1/15 0/15 2/15 7/15 3/15
  • Lung: alveolar/bronchiolar adenoma 0/15 1/15 0/15 1/15 4/15
Non-Neoplastic Lesions
  • Forestomach: epithelium hyperplasia
  • Brain: neuronopathy
  • Forestomach: epithelium hyperplasia
  • Brain: neuronopathy